Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as JBT-101 (lenabasum), anabasum
JBT-101 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| JBT101 (lenabasum) 1 mg | EXPERIMENTAL | JBT-101 1 mg once a day on Days 1-28 |
| JBT-101 (lenabasum) 5 mg | EXPERIMENTAL | JBT-101 5 mg once a day on Days 1-28 |
| Placebo | PLACEBO_COMPARATOR | Placebo once a day on Days 1-28. |
| JBT-101 (lenabasum) 20 mg QD | EXPERIMENTAL | JBT-101 20 mg once a day on Days 29-84. |
| JBT-101 (lenabasum) 20 mg BID | EXPERIMENTAL | JBT-101 20 mg twice daily on Days 29-84. |
| Placebo BID | PLACEBO_COMPARATOR | Placebo twice daily on Days 29-84. |
| Name | Type | Description |
|---|---|---|
| JBT-101 (lenabasum) | DRUG | Subjects will receive JBT-101 1 mg qd or JBT-101 5 mg qd on Days 1-28. Subjects will receive either JBT-101 20 mg q am (with placebo q pm) or JBT-101 20 mg twice a day on Days 29-84. |
| Placebo | OTHER | Subjects will receive placebo once a day on Days 1-28, placebo q pm on Days 29-84 (with JBT-101 20 mg q am), or placebo bid on Days 29-84. |
Inclusion Criteria: * Documentation of a CF diagnosis as evidenced by 1 or more clinical features consistent with the CF phenotype and 1 or more of the following criteria: 1. Sweat chloride equal to or greater than 60 mEq/L by quantitative pilocarpine iontophoresis test; 2. Two well-characteri...
Top 6 of 7 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | VRTX | 8 | PHASE3 | Alyftrek, Trikafta, Ivacaftor, VX-581, VX-272 |
| BiomX Inc. | PHGE | 1 | PHASE2 | BX004 |
| 4D Molecular Therapeutics, Inc. | FDMT | 1 | PHASE2 | 4D-710 |
| Arcturus Therapeutics Holdings, Inc. | ARCT | 1 | PHASE2 | ARCT-032 |
| Krystal Biotech, Inc. | KRYS | 1 | PHASE1 | KB407 |
| Roivant Sciences Ltd. | ROIV | 1 | PHASE1 | SP-101 |
JBT-101 is an investigational small molecule being studied for the treatment of cystic fibrosis. It has been evaluated in a Phase 2 clinical trial in adults with cystic fibrosis. It is not approved for any indication and remains in clinical development.
JBT-101 targets the CB2 receptor, a receptor target. By acting on CB2, the drug is designed to modulate receptor activity as part of its investigational mechanism in cystic fibrosis. It is a small molecule therapeutic.
JBT-101 is being developed by Corbus Pharmaceuticals Holdings, Inc., which trades under the ticker CRBP. The company is the sponsor of the clinical program evaluating the drug in cystic fibrosis.
JBT-101 is in Phase 2 development. It has completed one Phase 2 trial in cystic fibrosis. The drug is investigational and has not been approved by the FDA for any use.
JBT-101 has been studied in the Phase 2 trial NCT02465450, titled Safety, Tolerability, Pharmacokinetics, and Efficacy of JBT-101 (Lenabasum) in Cystic Fibrosis. The trial enrolled 85 participants across the United States, Belgium, France, Germany, Italy, Poland, and the United Kingdom, and it is completed.
Yes, JBT-101 is also known as lenabasum. The names refer to the same investigational small molecule developed by Corbus Pharmaceuticals for cystic fibrosis.